Data from Pre-Clinical Study of Protalex's PRTX-100 Compound to Be Presented at the Fifth International Conference on Autoimmunity in Sorrento, Italy.NEW HOPE, Pa. -- Protalex, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :PRTX) announced today that Joe J. Dervan, Ph.D., Director of Protein Chemistry and Biopharmaceutical Manufacturing at Protalex, will present pre-clinical efficacy data from the collagen induced arthritis study of the Company's PRTX-100 compound in development for the treatment of autoimmune and inflammatory diseases, at the Fifth International Conference on Autoimmunity, taking place November 29- December 3, 2006, at the Hilton Sorrento Palace Hotel, in Sorrento, Italy. The poster presentation is scheduled for Wednesday, November 29, 2006. About Protalex, Inc. Protalex, Inc. is a biotechnology company engaged in the development of a new class of drugs for the treatment of Rheumatoid Arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. (RA), Idiopathic Thrombocytopenic Purpura Idiopathic Thrombocytopenic Purpura Definition Idiopathic thrombocytopenic purpura, or ITP, is a bleeding disorder caused by an abnormally low level of platelets in the patient's blood. (ITP ITP - Intent to Package ), and a host of other autoimmune disorders Autoimmune Disorders Definition Autoimmune disorders are conditions in which a person's immune system attacks the body's own cells, causing tissue destruction. . Additional information about Protalex, Inc. can be found at www.protalex.com. Cautionary Statement Regarding Forward Looking Information This release contains forward-looking information about Protalex, Inc. that are intended to be covered by the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. for forward-looking statements provided by the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Forward-looking statements are statements that are not historical facts. These statements can be identified by the use of forward-looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology, and include discussions of strategy, and statements about industry trends and Protalex's future performance, operations and products. This forward-looking information should be considered only in connection with "Risk Factors" in Protalex's Annual Report on Form 10-KSB filed with the Securities and Exchange Commission ("SEC") on July 28, 2006 and its other periodic reports filed with the SEC. Protalex assumes no obligation to update any forward-looking statements or information set forth in this press release. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion